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Abstract
Background: The differences in total hip arthroplasty (THA) survivorship may be influenced by
individual susceptibility to periprosthetic osteolysis. This may be driven by functional
polymorphisms in the genes for cytokines and cytokine receptors involved in the development of
osteolysis in THA, thereby having an effect on the individual's phenotype.
Methods: We performed a study on 22 single-nucleotide polymorphisms (SNPs) for 11 cytokines
and two cytokine receptor candidate genes for association with severity of acetabular osteolysis
and risk to failure in THA. Samples from 205 unrelated Caucasian patients with cementless type
THA (ABG 1) were investigated. Distribution of investigated SNP variants between the groups of
mild and severe acetabular osteolysis was determined by univariate and multivariate analysis. Time-
dependent output variables were analyzed by the Cox hazards model.
Results: Univariate analysis showed: 1) TNF-238*A allele was associated with severe osteolysis
(odds ratio, OR = 6.59, p = 0.005, population attributable risk, PAR 5.2%); 2) carriers of the IL6-
174*G allele were 2.5 times more prone to develop severe osteolysis than non-carriers (OR =
2.51, p = 0.007, PAR = 31.5%); 3) the carriage of IL2-330*G allele was associated with protection
from severe osteolysis (OR = 0.55, p = 0.043). Based on logistic regression, the alleles TNF-238*A
and IL6-174*G were independent predictors for the development of severe acetabular osteolysis.
Carriers of TNF-238*A had increased cumulative hazard of THA failure according to Cox model (p
= 0.024). In contrast, IL2-330*G allele predicted lower cumulative hazard of THA failure (p =
0.019).
Conclusion:  Genetic variants of proinflammatory cytokines TNF-alpha and IL-6 confer
susceptibility to severe OL. In this way, presence of the minor TNF allele could increase the
cumulative risk of THA failure. Conversely, SNP in the IL2 gene may protect carriers from the
above THA complications.
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Background
Total hip arthroplasty (THA) is a procedure for alleviating
end-stage osteoarthritis with significant impact on the
quality of life in these patients [1]. However, the life-in-
service of joint implants is limited predominantly by
aseptic loosening and periprosthetic osteolysis both caus-
ally linked to wear debris that are generated continuously
by THA [2]. Phagocytosed wear particles provoke macro-
phages, fibroblasts and other cells to release proinflam-
matory cytokines and mediators that attract other
precursor cells. As a result, chronic inflammatory milieu
and a foreign body granuloma develop [3]. This, together
with direct inhibition of osteoblast function by wear par-
ticles [4], distorts homeostasis in bone in favour of exces-
sive bone resorption, i.e. osteolysis, which can lead to
aseptic loosening or periprosthetic fracture.
The concept of cytokines as initiators and perpetuators of
particle disease is supported by reports on proinflamma-
tory cytokine (IL-1, IL-6, TNF-α) up-regulation in macro-
phages and fibroblasts in response to wear particles [5,6].
These pleiotropic cytokines substantially promote the
recruitment and maturation of osteoclast precursors at the
bone-prosthesis interface [7]. Particle disease/osteolysis
might be also facilitated by down-regulation of immu-
nomodulatory cytokines with anti-osteoclastogenic prop-
erties (e.g. IL-4, IL-10, IFN-γ) as has been already
demonstrated in inflammatory joint conditions [8,9].
However, so called "particle disease" cannot sufficiently
explain either the variable degrees of osteolysis found in
patients with similar wear rates (and thus exposure to
wear particles) or differences in THA survivorship even in
the case of the same implant and similar wear rate [10].
For this reason, the concept of individual susceptibility to
osteolysis must play a role. Generally, the interaction
between the prosthesis and host can be influenced by sev-
eral less or well known mechanisms including the allergic
hypersensitivity, non-allergic and toxic response to a
material constituent of the implant [11,12]. Hypotheti-
cally, variation in genes for cytokines can alter gene func-
tion and/or expression which may affect the individual's
resistance/susceptibility to severe osteolysis [13]. In sup-
port of this concept, Wilkinson et al. reported increased
rate of osteolysis in patients carrying the A allele of the
TNF-238 single nucleotide polymorphism (SNP), [14].
Other studies have addressed variation in single genes for
other candidate molecules in relationship with aseptic
loosening [15-17]. Surprisingly, only one study reported
the variation in the axis of RANKL/RANK/OPG (at posi-
tion  RANK+575*T) that is considered the single most
influencing regulator of osteoclastogenesis [18]. Interest-
ing results were published by Gordon et al. on the associ-
ation of periprosthetic osteolysis and polymorphism in
genes for Wnt canonical pathway (FRZB 200Trp, FRZB
200Arg: 324Arg haplotype), [19]. Recently, the same team
identified the association between carriage of IL1RN
+2018*C allele and a decreased risk of osteolysis after
THA [20]. Taken together, none of the reported findings
has been replicated in independent samples thus still
being considered as preliminary. Therefore, researchers in
the field are strongly encouraged to perform well-organ-
ized replication studies to enable a meta-analysis [21].
This study was conducted to investigate the contribution
of genetic variation in proinflammatory/immunomodu-
latory cytokine genes to the risk of development of severe
periprosthetic osteolysis. In addition, this study addressed
the question whether there is an association between par-
ticular cytokine gene variants and risk of THA failure.
Methods
Subjects
Between February 2004 and June 2007 blood samples
were collected by venopuncture from 205 patients with
mild and severe acetabular bone defects around THA. The
subjects were divided into these two groups according to
the size of their acetabular bone defects. This was deter-
mined by the classification of Saleh et al. from preopera-
tive radiographs and confirmed intraoperatively [22].
Intraoperatively bone defects were evaluated distinguish-
ing at the acetabular site: no significant bone loss (type I),
contained bone loss (type II), moderate uncontained
bone loss (type III), severe uncontained bone loss (types
IV) and pelvic discontinuity (type V). Briefly, if patients
fulfilled the criteria for acetabular bone defects of type I
and II they were considered as having mild osteolysis (N
= 89) while others with more extensive bone defects
(types III to V) were classified as severe osteolysis (N =
116).
The study included only Czech Caucasian patients who
were operated on at a single institution and those with an
identical cementless prosthesis (ABG, Howmedica, Inc.,
Staines, England). The ABG 1 prosthesis was designed in
the 1980s as a press-fit hemispherical cup and anatomical
stem both with hydroxyapatite coating. All polyethylene
liners were ram-extruded from Hostalen GUR 4150 and
air-sterilized with 25 kGy gamma irradiation [23]. Our
local register was scrutinized for patients who were and
were not revised for osteolysis while the latter were chosen
from patients with the longest follow-up assuming those
are of "resistant genotype" against premature failure and
development of severe osteolysis (phenotypically mild
osteolysis). All patients were contacted and invited for
clinical and radiographic examination and blood sam-
pling. In patients with bilateral THA who were not revised
on either side by the day of blood sampling, the data for
hips with longer follow-up were included while in the
case of revision, the data for hips with shorter follow-upBMC Medical Genetics 2009, 10:109 http://www.biomedcentral.com/1471-2350/10/109
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were recorded. The reasons for that were similar as above,
i.e. hypothesized risk genotype for severe acetabular oste-
olysis development. Basic demographic and clinically-rel-
evant data for both study groups are shown in Table 1.
All hips included in the study had stable prosthesis at the
first year after index surgery. Interpretation of final radio-
graphs consisted of evaluation of implant stability, occur-
rence and extent of osteolysis. This was performed
according to well-known and validated criteria
[22,24,25]. In the revised cases (N = 157), the radio-
graphic findings were supplemented with intraoperative
findings. In this line, radiographic stability was re-coded
(=changed) to loosening in cases where an implant insta-
bility was revealed after a weak levering of special tools for
the cup/stem removal. Wear measurement was made
using a Universal-type measuring microscope in the
revised cases. Briefly, the methodology relies on the deter-
mination of nine three-dimensional coordinates on the
surface of the prosthetic ball fixed inside the retrieved pol-
yethylene cups in both the post-use and manufactured
positions. Based on it, the centre of the prosthetic ball at
each position and total wear can be calculated using the
special computational algorithm. Briefly, previously
reported accuracy of the method used for polyethylene
wear measurement ranged from 1 to 4 μm and 1 to 9 mm3
for linear and volumetric wear, respectively; reliability of
the method was also previously assessed [26,27].
All blood specimens were collected under the same condi-
tions. Written informed consent was obtained from each
subject and the study was approved by the Ethics Com-
mittee of Palacky University and Teaching Hospital in
Olomouc.
Genotyping of cytokine gene single nucleotide 
polymorphisms
Twenty-two SNPs distributed in 13 genes encoding
cytokines and cytokine receptors (IL-1α, IL-1β, IL-1R, IL-
1Ra, IL-4Rα, IL-12, IFN-γ, TGF-β, TNF-α, IL-2, IL-4, IL-6
and IL-10) were investigated (see Additional file 1). Can-
didate genes were chosen in order to reflect a wide spec-
trum of cytokines and their receptors which have been
shown to play a role in the development of osteolysis. The
SNPs were selected for each investigated gene based on
their previously reported or anticipated functional rele-
Table 1: Basic characteristics of the THA patients included in the study stratified according to the severity of osteolysis at the 
acetabular site.
Mild osteolysis
(Types I, II)
Severe osteolysis
(Types III-V)
p Value#
Patients, N 89 116
Gender (men/women) 35/54 33/83 p = 0.101
Age at index surgery 48 (27-58) 45 (24-68) p = 0.128
Primary diagnosis:
Osteoarthritis 35 13
Dysplastic hip 23 62 p < 0.001
Other diagnoses 31 41
BMI (kg/m2) 28.1 (20.3-35.7) 27.2 (16.0-42.6) p = 0.062
Revision (yes) 44 113 p < 0.001
Age at event* (years) 55 (34-69) 52 (29-77) p = 0.005
Time to event* (years) 9 (2-13) 6 (3-12) p < 0.001
Harris hip score 78 (14-96) 65 (28-98) p < 0.001
Prosthesis stable (yes) 82 86 p < 0.001
Linear wear rate (mm/year) 0.22 (0.04-0.92) 0.34 (0.04-2.52) p = 0.009
Data presented as median and range (minimum to maximum) in parentheses. # p values for comparison between the groups of patients with mild/
severe osteolysis were calculated by Chi-squared test or Mann-Whitney U test as appropriate. *The "event" was defined as THA revision for 
revised patients or the final visit for non-revised patients.BMC Medical Genetics 2009, 10:109 http://www.biomedcentral.com/1471-2350/10/109
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vance for cytokine expression and/or structure (e.g. [28]).
The location (function) of investigated SNPs within the
genes is listed in Additional file 1. The great majority of
chosen SNPs became the most widely studied within par-
ticular cytokine genes for their possible association with
diseases and they are currently considered as "clinically
associated" in public databases http://www.ncbi.nlm.
nih.gov/projects/SNP.
The technique for genotyping cytokine SNPs has been
described elsewhere [29]. Briefly, DNA was extracted from
peripheral blood by the standard salting-out procedure
[30] and the DNA was handled according to ethical rules.
Genotyping was done by polymerase chain reaction with
sequence-specific primers (PCR-SSP) using the Heidel-
berg kit (Cytokine Typing Tray kit, University of Heidel-
berg, Heidelberg, Germany). The protocol has been
described elsewhere http://www.ihwg.org/components/
cytokine/CytokineManualII.rtf. In total, 5000 SNP geno-
typings were performed. We succeeded in assigning the
genotype in more than 98% of genotyped samples/SNPs.
The nomenclature for the investigated SNPs was adopted
from the manual of the Heidelberg kit (Lot No. CYT11).
Despite using the typing kit already validated by us [29]
and others [31], a subset of six SNPs in IL1A, IL1B, IL6,
and TNF genes was tested for genotyping concordance by
"in-house" PCR-based methodologies [32,33].
Study design and statistical analysis
This study investigated eventual associations between
severity of acetabular osteolysis in THA (primary out-
come) and twenty-two SNPs across eleven genes coding
for proinflammatory/immunomodulatory cytokines and
also for two cytokine receptor genes, all located across ten
chromosomes. Distribution of investigated SNP variants
was compared by univariate analysis between the groups
of patients with severe (N = 116) and mild (N = 89) oste-
olysis. Three SNPs emerging from this analysis were tested
also for association with secondary outcome of the study,
i.e. cumulative hazard of THA failure. The revision of THA
was considered as the end point in this analysis although
it is known that the decision-making on the timing of revi-
sion depends on several factors including those unrelated
to the prosthesis failure [34]. Subsequently, a multivariate
analysis using logistic regression was performed in order
to evaluate interactions of different covariates on the pri-
mary outcome. Finally, association of investigated
cytokine SNP variants with secondary outcome of the
study (cumulative hazard of THA failure) was adjusted for
severity of osteolysis.
Comparison of genotypes and carriage rates
Univariate analysis was performed by comparisons of
genotype and phenotype frequencies between subgroups
of THA patients using χ2 test; the term 'phenotype fre-
quency' (i.e., carriage rate) gives the number of subjects
carrying one (or two) copies of a particular allele on one
or both (maternal and paternal) chromosomes. Odds
ratios (OR) were calculated for carriers of risk allele com-
pared to non-carriers. Population attributable risk (PAR)
was calculated according to the protocol described else-
where [35]. χ2  goodness-of-fit test which compares
observed and expected genotype numbers for each inves-
tigated SNP was used to test for deviation of genotype dis-
tribution from the Hardy-Weinberg (H-W) equilibrium. P
value less than 0.05 was considered as significant.
Cumulative estimates and other statistics
Multivariate analyses using logistic regression were per-
formed by forward stepwise (likelihood ratio) method.
Cox regression analysis was used to assess cumulative haz-
ard of revision after THA. The time to the event was deter-
mined as the time that elapsed since THA implantation to
the date of revision or until the final follow-up, whichever
occurred first. Homogeneity of the groups was tested
using the Chi-squared and Mann-Whitney U tests. All sta-
tistics were calculated with the SPSS 15.0 (SPSS Inc, Chi-
cago, IL, USA).
Results
Clinical outcome of patients with THA according to the 
severity of OL
Patients with severe osteolysis had significantly lower
Harris Hip Score at the last follow-up in comparison with
those with mild osteolysis (mean 65 versus 78 points, p <
0.001). They were revised in 113/116 (97.4%) cases in
comparison with 44/89 (49.4%, p < 0.001) of patients
with mild osteolysis. THA was classified as "stable" in
74.1% (86/116) and 92.1% (82/89) in patients with
severe and mild osteolysis (p < 0.001), respectively. Fur-
thermore, patients with severe osteolysis were character-
ised by shorter time to revision/final checking out
(median 6 years) when compared with mild osteolysis
group (median 9 years; p < 0.001). The reasons for revi-
sion were as follows: osteolysis around a stable cup 85/34
(in groups with severe/mild osteolysis), aseptic loosening
of the cup 27/7 and periprosthetic fracture 3/1. The most
frequent location of acetabular osteolysis was zone II
(88%) in revised cases according to DeLee and Charnley
classification [36]. In unrevised cases, location of osteoly-
sis was in zone II (42%) followed by zones I (28%) and
III (12%).
The distribution of cytokine/cytokine receptor gene SNPs 
in THA patients
To determine the distribution of the twenty two cytokine/
cytokine receptor SNPs, the group of 205 well-character-
ised THA patients was genotyped using PCR-SSP tech-
nique. Of the 22 investigated SNPs, the distribution of
genotypes deviated from the Hardy-Weinberg (H-W)BMC Medical Genetics 2009, 10:109 http://www.biomedcentral.com/1471-2350/10/109
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equilibrium for one SNP in the group of THA patients as
a whole (TGFB1 codon 25: p = 0.01).
However, we did not observe any deviation from H-W
equilibrium for this SNP in our sample of Czech healthy
subjects investigated by the same methodology [29]. Fur-
thermore, the deviation of TGFB1 codon 25 SNP could
occur due to the random fluctuation when H-W testing for
multiple markers was applied. We, therefore, used data on
this TGFB1 SNP for further analyses with caution. This
approach is in compliance with the current recommenda-
tions for the reporting of genetic association studies [37].
Association of investigated cytokine/cytokine receptor 
gene SNPs with severity of acetabular OL in THA
Of 22 analysed cytokine/cytokine receptor SNPs, the pro-
portion of TNF-238*A allele carriers was higher among
the patients with severe than mild osteolysis (OR = 6.59,
p = 0.005, PAR = 5.2%, Figure 1A). Similarly, carriers of
the  IL6-174*G allele were overrepresented among
patients with severe osteolysis compared to those with
mild osteolysis (OR = 2.51, p = 0.007, PAR = 31.5%, Fig-
ure 1B). By contrast, the IL2-330*G allele was underrepre-
sented in patients with severe osteolysis in comparison to
those with mild ostelysis (OR = 0.55, p = 0.043, Figure 1C)
and, thus, appeared to protect against severe osteolysis.
Multivariate analysis of primary outcome (severity of oste-
olysis) used regression model including age at index THA,
gender, weight/height, primary diagnosis, linear wear rate
(LWR) and genetic variants (TNF-238*A, IL6-174*G, IL2-
330*G). In this analysis, primary diagnosis (p = 0.002)
and LWR (p = 0.004) significantly predicted severe osteol-
ysis. Because LWR covariate strongly limited analysis [it
was measured only in revised cases - 157/205 of all THA
patients, 76.5%], it was removed from the final regression
analysis. In a model without LWR the alleles TNF-238*A
(p = 0.045) and IL6-174*G (p = 0.049) appeared to be fur-
ther predictors for the development of more severe acetab-
ular osteolysis, but the contribution of IL2-330*G allele
was not apparent here.
Cumulative risk of THA failure and its relationship to the 
cytokine/cytokine receptor gene SNPs
Since the rate of THA revision is considered the most crit-
ical parameter in assessing THA outcome and at the same
time aseptic loosening together with periprosthetic osteol-
ysis is the most frequent cause of THA failure, we were
interested in whether cumulative hazard of THA failure
(defined as a revision due to aseptic loosening or osteoly-
sis) was associated with cytokine/cytokine receptor SNP
variants. In agreement with the observed associations of
the TNF-238*A allele with severe osteolysis, TNF-238*A
carriers were characterised by increased cumulative hazard
of THA failure compared to patients with the TNF-238 GG
genotype (p = 0.024, Figure 2A). However, the presence of
the IL6-174*G allele in THA patients did not change the
cumulative hazard of THA failure. On the other hand, the
protective effect of the IL2-330*G allele was further con-
firmed in terms of lower cumulative hazard of THA failure
in IL2-330*G allele carriers compared to non-carriers (p =
0.019, Figure 2B). Nevertheless, neither TNF-238*A nor
IL2-330*G alleles predicted changes in the cumulative
hazard of THA failure independently from osteolysis as
was seen after adjustment of Cox regression analysis for
the severity of osteolysis.
Discussion
This comprehensive study investigated the association
between extent of acetabular osteolysis in THA and poly-
morphic variants across a wide spectrum of genes encod-
ing for cytokines/cytokine receptors with inflammatory
and/or immunomodulatory properties. In particular, the
study suggests that SNPs in genes for proinflammatory
cytokines TNF-α and IL-6 may play a role in the pathogen-
esis of osteolysis. In addition, a SNP in the gene for the
Th1 cytokine IL-2 was found to be a factor associated with
severity of acetabular osteolysis and risk for premature
THA failure.
In this study, carriage of the TNF-238*A allele was associ-
ated with severe acetabular osteolysis and risk for prema-
ture failure in contrast to the TNF-238 "GG" genotype.
Individuals carrying the TNF-238*A were six times more
prone to develop severe osteolysis than patients with the
GG genotype. Accordingly, the striking risk for severe
acetabular osteolysis associated with TNF-238*A carriage
could be detected here at statistically significant level
though this variant is relatively rare (see power calcula-
tions in Additional file 1). Our study, therefore, confirms
that TNF-238 SNP plays a role in the development of oste-
olysis as suggested by Wilkinson et al. [14]. Concerning
another SNP in TNF gene promoter, our findings are con-
cordant to those of Wilkinson et al. and Kolundzic et al.
[17], who found no relationship between the carriage of
the TNF-308*A allele and risk for osteolysis development
or premature prosthetic failure.
To properly evaluate the contribution of SNPs in the TNF
gene to osteolysis development and prognosis of THA, it
should be acknowledged that the minor TNF-238*A allele
occurs rarely in the normal population, limiting its contri-
bution to the overall "population" risk of severe acetabu-
lar osteolysis (PAR value, 5.2%). This SNP may, however,
serve as a marker for other causative polymorphism(s) in
the TNF locus or neighbouring polymorphic major histo-
compatibility complex (MHC) genes. This interpretation
would be also in accordance with equivocal data from in
vitro/ex vivo analyses of the functional influence of TNF-
238 and also TNF-308 polymorphisms on TNF gene tran-BMC Medical Genetics 2009, 10:109 http://www.biomedcentral.com/1471-2350/10/109
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Comparison of proportion of TNF-238*A (A), IL6-174*G (B), and IL2-330*G (C) allele carriers in the groups of patients with  severe and mild osteolysis Figure 1
Comparison of proportion of TNF-238*A (A), IL6-174*G (B), and IL2-330*G (C) allele carriers in the groups of 
patients with severe and mild osteolysis. Comparison severe versus mild osteolysis: TNF-238*A: p = 0.005, OR = 6.59 
(95% CI: 1.47-29.64), PAR% = 5.2. IL6-174*G: p = 0.007, OR = 2.51, (95% CI: 1.27-4.98), PAR% = 31.5. IL2-330*G: p = 0.043, 
OR = 0.55, (95% CI: 0.31-0.98). OR: odds ratio, CI: confidence interval, PAR%: population attributable risk percentageBMC Medical Genetics 2009, 10:109 http://www.biomedcentral.com/1471-2350/10/109
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Comparison of cumulative hazard of THA failure between the carriers (green curve) and non-carriers (blue curve) of TNF- 238*A (A) and IL2-330*G (B) alleles assessed by Cox regression analysis Figure 2
Comparison of cumulative hazard of THA failure between the carriers (green curve) and non-carriers (blue 
curve) of TNF-238*A (A) and IL2-330*G (B) alleles assessed by Cox regression analysis. TNF-238*A vs. TNF-238 GG 
homozygotes: p = 0.024. IL2-330*G vs. IL2-330 TT homozygotes: p = 0.019.BMC Medical Genetics 2009, 10:109 http://www.biomedcentral.com/1471-2350/10/109
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scription and subsequent cytokine expression, processes
which seem to be highly cell or stimulus specific [38,39].
A SNP in the IL6 gene promoter was another polymor-
phism implicated in the pathogenesis of OL in this study.
IL-6 is a multifunctional cytokine also involved in the reg-
ulation of bone metabolism; therefore its participation in
the processes occurring at the bone-prosthesis interface is
plausible [6]. Here, IL6-174*G allele carriage was associ-
ated with the increased risk of severe osteolysis according
to both the univariate and multivariate analyses. How-
ever, this SNP in gene for IL-6 did not influence the risk
for cumulative hazard of THA failure. Association of IL6-
174*G with severe osteolysis could not currently be sup-
ported by straightforward "mechanistic" explanation
because its functional role on IL-6 expression is controver-
sial. The allele IL6-174*G was originally associated with
higher induced expression of IL-6 in vitro [40], however
this was not subsequently confirmed [41]. Importantly,
Terry et al. revealed that effect of IL6 genetic variation on
IL-6 expression is tissue-specific and dependent on other
environmental factors [41,42]. This observation may
explain the opposite roles of IL6-174 SNP observed in dif-
ferent clinical conditions [40,43,44]. Our results, there-
fore, allow us to speculate that complex local response
around THA provides adequate conditions/stimuli pro-
moting "penetrance" of the IL6-174 variant in terms of its
effect on IL-6 expression. Concerning previous findings
on IL6 gene in THA outcome, Malik et al. [16] like us,
reported no association of IL6-174 SNP with the risk of
premature failure of cemented THA. The association of
the IL6 SNP (positions -597 and -572) with the earlier
prosthetic failure has been reported by Kolundzic et al.
[17]. However, their study had a small number of patients
and included both hips in the same patient into the anal-
ysis.
Based on our data the IL2-330*G genetic variant may
function protectively against severe osteolysis which
could result in significantly lower cumulative hazard of
THA failure. Interestingly, Campos et al. [45] found that
polymorphism in the IL2-330*G was not associated with
premature failure of dental implants. Due to biological
and mechanical similarities between THA and dental
implants, both studies suggest a protective role of IL2 SNP
on the prosthetic-bone interface. IL-2 regulates both sur-
vival and death of regulatory T cells which might affect the
osteoclast life cycle [46]. However, the functional rele-
vance of the investigated IL2 SNP is not clear [47,48] and
thus the role of IL-2, and therefore also Th1 lymphocytes
in the pathogenesis of periprosthetic osteolysis has yet to
be elucidated [11]. Whatever the mechanism behind pos-
sible IL-2 participation in pathological processes around
THA, if proven in other centres/populations, the protec-
tive effects of the IL2-330*G would have clear implica-
tions because the G allele is carried by more than 50% of
Europeans [29,49].
While interpreting the results of the current study, one
should consider the theory of multifactorial susceptibility
to complex disease and current issues of genetic associa-
tion studies (GAS). Any individual genome contains
many functional variants and many of these can influence
the development of osteolysis in conjunction with other
biological, mechanical and material factors. Furthermore,
one may also conceivably argue that other genetic "ele-
ments" than those identified in this study may be
involved in the complex process of particular disease via
phenomenon of linkage disequilibrium [50]. Future
investigations should be directed at detailed analyses of
specified candidate regions on chromosomes 4q, 6p and
7q in order to search for further genetic markers of osteol-
ysis developing after THA. Finally, based on current expe-
rience showing that the great proportion of GAS has not
been replicated in independent samples, further valida-
tion through replication studies is strictly recommended
[51]. In this regard, it should be emphasised that our
study replicated the findings of Wilkinson et al. for TNF-
238*A [14].
Limitations and strengths of our study
We are aware that relative heterogeneity of the primary
diagnoses leading to index THA may be linked to the THA
outcome including osteolysis. Nevertheless, genetic vari-
ants of cytokine genes (namely TNF-238*A and IL6-
174*G) appeared to be independent predictors of severe
osteolysis after adjustment for primary diagnosis and
other relevant factors in the regression analysis. Moreover,
the vast majority of dysplastic hips (over 98%) were of
Hartofilakidis type I which influence the THA survival
only insignificantly, and the remaining ones were of type
II [52]. In addition, selection bias might have an influence
on the reported findings because not all patients with the
ABG 1 prosthesis could be included in the study (205 of
506). In non-revised cases the severity of bone defects was
determined primarily from radiography which could have
led to underestimation of the true bone defects. Despite
the rigorously created design of this association study,
false positive findings cannot be excluded. On the other
hand, only patients with identical prosthesis were
included which eliminated the influence of inter-pros-
thetic differences on osteolysis development and pros-
thetic failure. In addition, surgery was performed at the
single institution by a limited number of experienced sur-
geons which should minimize the role for surgery-related
differences on failure of the implant.
Also from the genetic epidemiology view, our study meets
the recently adopted criteria for GAS [21]. Apart from
emphasis on its preliminary character, this study had ade-BMC Medical Genetics 2009, 10:109 http://www.biomedcentral.com/1471-2350/10/109
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quate study power (more than 80% in 19 of 22 investi-
gated SNPs; see Additional file 1) and adhered to quality
control methods in genotyping/analytical methodologies
[29]; overall genotyping "failure" rate was very low (less
than two percent). Importantly, the parameter of PAR was
included to estimate the specific contribution of investi-
gated genetic markers among other complex individual
and environmental factors promoting development of
severe acetabular osteolysis and premature THA failure.
Conclusion
This case-control study associated gene polymorphisms in
two proinflammatory cytokines TNF-α and IL-6 with
extent of acetabular osteolysis. In addition, the risk for
THA failure was increased in carriers of TNF-238*A allele.
In contrast, a polymorphism of the gene for regulatory
Th1 cytokine IL-2 emerged as a possible factor protecting
against premature failure of THA and was negatively asso-
ciated with osteolysis severity in univariate analysis. Col-
lectively, the data expand the current paradigm of
osteolysis as a predominantly inflammatory process and
may implicate T-cells and their modulatory cytokines in
the particle disease. If this single-centre data are replicated
in other centres/population, new avenues will be opened
up for the use of genetic testing in pre-surgical stages and
also for investigation of immune response modulation in
THA.
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